Eli Lilly and Company (LLY)
More Records Highs for Eli Lilly Stock After Buyout
Eli Lilly And Co (NYSE:LLY) announced earlier today it will acquire Morphic Holding (NASDAQ:MORF) for $3.2 billion in cash, expanding its inflammatory bowel disease (IBD) drug portfolio.
3 No-Brainer Stocks to Buy in July
Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.
Recession Alert: Play Defense While Earning Up To 10% Yield
Don't fear recessions; embrace them with a well-constructed portfolio. Market prices and business fundamentals are distinct elements. Focus on the latter. We discuss two picks from non-discretionary sectors — telecom and healthcare.
Eli Lilly Remains an Equities Outlier
New obesity and Alzheimer's disease treatments are keeping Eli Lilly and Company (LLY) at the forefront of equities excellence.
Eli Lilly Stock Price Prediction: Where Will It Be in 1 Year
24/7 Insights Wall Street expectations for where Eli Lilly and Co.
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Zepbound and Mounjaro will add tens of billions in revenue to Eli Lilly's top line in the years ahead. But management is looking beyond those products and developing even more weight loss treatments.
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
On Tuesday, the FDA approved Eli Lilly and Co's LLY Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.
FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
Eli Lilly (LLY) has received Food and Drug Administration (FDA) approval for its treatment for early symptomatic Alzheimer's after studies showed that the drug was able to slow the progression of the disease.
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval
Eli Lilly's new Alzheimer's drug, Kisunla, shows promise with its unique treatment regimen and potential competitive advantages over Biogen's Leqembi. Despite challenges, Kisunla is priced aggressively at $32,000 per year, offering a potentially more cost-effective solution given its shorter treatment duration. Eli Lilly reported a 26% increase in revenue in Q1, driven by strong performances from its diabetes and obesity drugs.
Eli Lilly's Alzheimer's drug receives FDA sign-off
The Food and Drug Administration (FDA) has approved Eli Lilly and Co's (NYSE:LLY) new Alzheimer's drug, donanemab, to be sold under the brand name Kisunla. This monoclonal antibody infusion, administered every four weeks, targets amyloid in the brain, a hallmark of Alzheimer's disease.
